TransThera Sciences (Nanjing), Inc. ("TransThera”) (02617.HK), invested by TIBS and related funds, was officially listed and commenced trading on the Hong Kong Stock Exchange at 9:00 AM today. The company globally offered 15.281 million shares, with Hong Kong public offering accounting for 20% and international offering for 80%. The offering price per share was HKD 13.15.

Established in 2014, TransThera is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule innovative therapies for oncology, inflammation, and cardio-metabolic diseases, guided by clinical needs. Leveraging deep research in translational medicine and drug design. TransThera has built a rich R&D pipeline including 1 core product, 5 clinical-stage drug candidates, and 1 preclinical-stage drug candidate, demonstrating strong continuous innovation capabilities.

The company's core product, Tinengotinib, has received high recognition from regulatory authorities in China, the US, and Europe. It has not only been granted Breakthrough Therapy Designation by China's NMPA, but also secured FDA Fast Track Designation and Orphan Drug Designation, as well as EMA Orphan Drug Designation, fully showcasing its international competitiveness. Currently, Tinengotinib is undergoing Phase III registrational clinical studies in China and globally for the last-line cholangiocarcinoma indication, for which there are currently no effective treatments. It is expected to submit a new drug application in China within 2025 and has the potential to be expanded to treat more last-line tumour indications. TransThera’s core product, Tinengotinib, possesses significant clinical value and market potential.

TIBS and related funds participated in TransThera’s D+ round financing in December 2022.

Read more about TransThera IPO news here